Nishihama K, Okano Y, Inoue C, Maki K, Eguchi K, Tanaka S
Diabetol Int. 2024; 15(3):583-588.
PMID: 39101192
PMC: 11291771.
DOI: 10.1007/s13340-024-00703-y.
Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T
Front Endocrinol (Lausanne). 2024; 15:1407192.
PMID: 38841300
PMC: 11150800.
DOI: 10.3389/fendo.2024.1407192.
Angelousi A, Ziogas D, Siampanopoulou V, Mytareli C, Anastasopoulou A, Lyrarakis G
Diseases. 2024; 12(2).
PMID: 38391787
PMC: 10887699.
DOI: 10.3390/diseases12020040.
Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K
Front Public Health. 2023; 11:1264056.
PMID: 38106883
PMC: 10725247.
DOI: 10.3389/fpubh.2023.1264056.
Liu Y, Liu H, Zhao S, Chen K, Jin P
Front Immunol. 2023; 14:1164120.
PMID: 37359544
PMC: 10288983.
DOI: 10.3389/fimmu.2023.1164120.
Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors.
Inaba H, Morita S, Kosugi D, Asai Y, Kaido Y, Ito S
Front Immunol. 2023; 14:1165004.
PMID: 37114039
PMC: 10128036.
DOI: 10.3389/fimmu.2023.1165004.
Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J, Luo S, Yin W, Li X, Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(1):49-58.
PMID: 36935177
PMC: 10930557.
DOI: 10.11817/j.issn.1672-7347.2023.220290.
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment.
Shalit A, Sarantis P, Koustas E, Trifylli E, Matthaios D, Karamouzis M
Cancers (Basel). 2023; 15(2).
PMID: 36672324
PMC: 9856539.
DOI: 10.3390/cancers15020375.
Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature.
Yan J, Xie Z, Moran T, Gridelli C, Zheng M, Dai S
Ann Transl Med. 2022; 10(22):1256.
PMID: 36544678
PMC: 9761142.
DOI: 10.21037/atm-22-5211.
Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
Qiu J, Luo S, Yin W, Guo K, Xiang Y, Li X
Front Immunol. 2022; 13:968798.
PMID: 36451831
PMC: 9702060.
DOI: 10.3389/fimmu.2022.968798.
PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.
Lin C, Li X, Qiu Y, Chen Z, Liu J
Front Public Health. 2022; 10:885001.
PMID: 35991054
PMC: 9389003.
DOI: 10.3389/fpubh.2022.885001.
Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review.
Zheng Z, Wang J, Li W, Wu T, Chen M, Zhou Z
Front Public Health. 2022; 10:917679.
PMID: 35784237
PMC: 9243496.
DOI: 10.3389/fpubh.2022.917679.
The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I, Pandey M, Sharma R, Chaudhuri A, Dandona P
Indian J Med Res. 2022; 154(4):559-570.
PMID: 35435341
PMC: 9205006.
DOI: 10.4103/ijmr.IJMR_313_19.
Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.
Inaba H, Kaido Y, Ito S, Hirobata T, Inoue G, Sugita T
Endocrinol Metab (Seoul). 2022; 37(1):84-95.
PMID: 35255603
PMC: 8901959.
DOI: 10.3803/EnM.2021.1282.
Sintilimab-induced autoimmune diabetes: A case report and review of the literature.
Yang J, Wang Y, Tong X
World J Clin Cases. 2022; 10(4):1263-1277.
PMID: 35211559
PMC: 8855200.
DOI: 10.12998/wjcc.v10.i4.1263.
Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A, Almuwais A, Gibbons H
BMJ Case Rep. 2022; 15(1).
PMID: 35039353
PMC: 8768469.
DOI: 10.1136/bcr-2021-245846.
Cardiometabolic Consequences of Targeted Anticancer Therapies.
Guha A, Gong Y, DeRemer D, Owusu-Guha J, Dent S, Cheng R
J Cardiovasc Pharmacol. 2021; 80(4):515-521.
PMID: 34654781
PMC: 8977391.
DOI: 10.1097/FJC.0000000000001149.
Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases.
Fujiwara N, Watanabe M, Katayama A, Noda Y, Eguchi J, Kataoka H
Clin Case Rep. 2021; 9(9):e04574.
PMID: 34522382
PMC: 8424178.
DOI: 10.1002/ccr3.4574.
Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
Huang X, Yang M, Wang L, Li L, Zhong X
Medicine (Baltimore). 2021; 100(19):e25795.
PMID: 34106616
PMC: 8133135.
DOI: 10.1097/MD.0000000000025795.
Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.
Liu Y, Zhang H, Zhou L, Li W, Yang L, Li W
Front Oncol. 2021; 11:627612.
PMID: 33732647
PMC: 7959713.
DOI: 10.3389/fonc.2021.627612.
